Abstract:Various gold complexes have been known to overcome cisplatin resistance in cancer cells. Yet, their in vivo anti-tumor efficacies and detailed action mechanisms in overcoming this resistance remain largely unexplored. In this work we have established a xenograft model simultaneously consisting of both cisplatin-sensitive and cisplatin-resistant tumors by inoculating human ovarian cancer cells A2780 and its cisplatin-resistant variant A2780cis into different flanks of the same nude mouse. Towards this model, a gold(III) porphyrin complex [Au-III(TPP)]Cl (gold-1a, wherein [TPP](2-) = meso-tetraphenylporphyrinato ligand) was found to effectively inhibit the growth of both kinds of tumors, while cisplatin failed to suppress the growth of A2780cis tumors under similar conditions. In both A2780 and A2780cis cells, gold-1a was found to transcriptionally upregulate postmeiotic segregation increased 2 (PMS2) which has DNA mismatch repair and proapoptotic functions. Suppression of PMS2 by RNA interference in A2780cis cells partially rescued the gold-1a-induced death of the cells, indicating that gold-1a inhibited growth of cisplatin-resistant ovarian cancer in association with upregulation of this gene. Two other stable gold(III) analogues including gold(III) octaethylporphyrin (2) and gold(III)-NHC (3) complexes also displayed similar anti-cancer activities on A2780cis cells and capability in PMS2 regulation. In contrast, a gold(I) phosphine complex (4), a gold(I) thiourea complex (5), (KAuCl4)-Cl-III and cisplatin all displayed a preferential cytotoxicity only towards the cisplatin-sensitive A2780 cells. Taken together, this work has demonstrated the prospect of gold(III) complexes for the treatment of cisplatin-resistant/relapsed ovarian cancers.

Organometallic gold(I) and gold(III) complexes for lung cancer treatment

Gold complexes: a new frontier in the battle against lung cancer

Recent development of Schiff-base metal complexes as therapeutic agents for lung cancer

Towards the Rational Design of Platinum(ii) and Gold(iii) Complexes As Antitumour Agents

Anticancer Activity of Imidazolyl Gold(I/III) Compounds in Non-Small Cell Lung Cancer Cell Lines

Ruthenium Complexes as Promising Candidates against Lung Cancer

ChemInform Abstract: Chemical Biology of Anticancer Gold(III) and Gold(I) Complexes

Current status of iridium-based complexes against lung cancer

Gold(III) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 gene.

Gold Complexes and Their Molecular Targets in Colorectal Cancer

Synthesis, Characterization and Antitumor Activity of Novel Gold (III) Compounds with Cisplatin-Like Structure

Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment

Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems

Cyclometalated Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands Engage Multiple Anti-Cancer Molecular Targets.

Enhancement of gold-nanocluster-mediated chemotherapeutic efficiency of cisplatin in lung cancer

Research progress of natural product-conjugated platinum and gold complexes as potential antitumor agents

Metal-N-heterocyclic carbene complexes as anti-tumor agents

Rational Design of Multi-Targeting Ruthenium- and Platinum-Based Anticancer Complexes

Synthesis and biological evaluation of novel bi-gold mitocans in lung cancer cells

Deubiquitinases As Anticancer Targets of Gold Complexes

Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents